Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics


Aurinia Pharmaceuticals Inc (AUPH): $15.67

1.02 (+6.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AUPH POWR Grades


  • AUPH scores best on the Value dimension, with a Value rank ahead of 53.12% of US stocks.
  • AUPH's strongest trending metric is Growth; it's been moving up over the last 169 days.
  • AUPH ranks lowest in Stability; there it ranks in the 2nd percentile.

AUPH Stock Summary

  • With a price/sales ratio of 26.3, Aurinia Pharmaceuticals Inc has a higher such ratio than 94.24% of stocks in our set.
  • Revenue growth over the past 12 months for Aurinia Pharmaceuticals Inc comes in at 61,635.9%, a number that bests 100% of the US stocks we're tracking.
  • The volatility of Aurinia Pharmaceuticals Inc's share price is greater than that of 92.52% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Aurinia Pharmaceuticals Inc are VTVT, APLS, PRTA, SAGE, and GMBL.
  • Visit AUPH's SEC page to see the company's official filings. To visit the company's web site, go to www.auriniapharma.com.

AUPH Valuation Summary

  • In comparison to the median Healthcare stock, AUPH's price/sales ratio is 219.82% higher, now standing at 36.3.
  • AUPH's EV/EBIT ratio has moved down 0.1 over the prior 85 months.
  • AUPH's price/sales ratio has moved down 88 over the prior 85 months.

Below are key valuation metrics over time for AUPH.

Stock Date P/S P/B P/E EV/EBIT
AUPH 2021-08-31 36.3 6.3 -13.6 -12.8
AUPH 2021-08-30 37.9 6.6 -14.2 -13.5
AUPH 2021-08-27 39.5 6.8 -14.8 -14.0
AUPH 2021-08-26 40.0 6.9 -14.9 -14.2
AUPH 2021-08-25 36.7 6.4 -13.7 -13.0
AUPH 2021-08-24 34.1 5.9 -12.8 -12.0

AUPH Growth Metrics

    Its year over year cash and equivalents growth rate is now at -42.89%.
  • The 2 year net income to common stockholders growth rate now stands at -272.72%.
  • Its 3 year cash and equivalents growth rate is now at 3919.44%.
Over the past 33 months, AUPH's revenue has gone up $71,768,000.

The table below shows AUPH's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 72.231 -126.313 -170.2
2021-06-30 57.593 -116.343 -154.009
2021-03-31 51.002 -100.958 -136.525
2020-12-31 50.118 -69.858 -102.68
2020-09-30 0.117 -100.867 -156.604
2020-06-30 0.318 -82.362 -141.577

AUPH's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AUPH has a Quality Grade of D, ranking ahead of 9.07% of graded US stocks.
  • AUPH's asset turnover comes in at 0.178 -- ranking 206th of 682 Pharmaceutical Products stocks.
  • SVRA, SESN, and VSTM are the stocks whose asset turnover ratios are most correlated with AUPH.

The table below shows AUPH's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.178 0.992 -0.759
2021-06-30 0.133 0.994 -0.753
2021-03-31 0.125 0.999 -0.874
2020-12-31 0.131 1.000 -1.010
2020-09-30 0.000 1.000 -2.541
2020-06-30 0.001 1.000 -10.800

AUPH Price Target

For more insight on analysts targets of AUPH, see our AUPH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.03 Average Broker Recommendation 1.31 (Strong Buy)

AUPH Stock Price Chart Interactive Chart >

Price chart for AUPH

AUPH Price/Volume Stats

Current price $15.67 52-week high $33.97
Prev. close $14.65 52-week low $9.72
Day low $14.12 Volume 3,759,801
Day high $15.77 Avg. volume 3,314,611
50-day MA $20.23 Dividend yield N/A
200-day MA $17.77 Market Cap 2.01B

Aurinia Pharmaceuticals Inc (AUPH) Company Bio


Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.


AUPH Latest News Stream


Event/Time News Detail
Loading, please wait...

AUPH Latest Social Stream


Loading social stream, please wait...

View Full AUPH Social Stream

Latest AUPH News From Around the Web

Below are the latest news stories about Aurinia Pharmaceuticals Inc that investors may wish to consider to help them evaluate AUPH as an investment opportunity.

Liontrust Investment Partners LLP Buys PayPal Holdings Inc, DocuSign Inc, Illumina Inc, Sells ...

Investment company Liontrust Investment Partners LLP (Current Portfolio) buys PayPal Holdings Inc, DocuSign Inc, Illumina Inc, NVR Inc, Otis Worldwide Corp, sells Moderna Inc, Brookfield Infrastructure Corp, 3M Co, Mobile TeleSystems PJSC, Twilio Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Liontrust Investment Partners LLP.

Yahoo | January 26, 2022

Kestra Private Wealth Services, Llc Buys FT Cboe Vest Fund of Deep Buffer ETFs, iShares Core U. ...

Investment company Kestra Private Wealth Services, Llc (Current Portfolio) buys FT Cboe Vest Fund of Deep Buffer ETFs, iShares Core U.S.

Yahoo | January 21, 2022

First Midwest Bank Trust Division Buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares ...

Joliet, IL, based Investment company First Midwest Bank Trust Division (Current Portfolio) buys Axsome Therapeutics Inc, PROSHARES TRUST, iShares Russell Mid-Cap ETF, ISHARES TRUST, Aurinia Pharmaceuticals Inc, sells Iovance Biotherapeutics Inc, Consumer Discretionary Select Sector SPDR, AT&T Inc, Avis Budget Group Inc, Cerus Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First Midwest Bank Trust Division.

Yahoo | January 18, 2022

Aurinia Pharmaceuticals reverses decline after report on potential M&A interest

Aurinia Pharmaceuticals (NASDAQ:AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (NASDAQ:BIIB) could potentially look to target the company. Aurinia (AUPH) was down earlier at least party after the company presented at two conferences today, though no M&A was mentioned. Now the shares are moving higher...

Seeking Alpha | January 13, 2022

Aurinia Pharmaceuticals drops amid silence on M&A after conference presentations

Aurinia Pharmaceuticals (NASDAQ:AUPH) ticked down 1.7% after the company presented at two conferences today, though no M&A was mentioned. Aurinia Pharma (AUPH) presented earlier at the JPMorgan Healthcare conference and a H.C. Wainwright conference. Aurinia has been the subject of rampant takeover speculation in recent months after Bloomberg reported in late October...

Seeking Alpha | January 13, 2022

Read More 'AUPH' Stories Here

AUPH Price Returns

1-mo -30.32%
3-mo -52.63%
6-mo 15.56%
1-year -8.26%
3-year 148.73%
5-year 386.65%
YTD -31.48%
2021 65.37%
2020 -31.74%
2019 197.07%
2018 50.55%
2017 115.71%

Continue Researching AUPH

Here are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:

Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.2596 seconds.